The Cooper Companies Inc (COO)
99.91
+0.83
(+0.84%)
USD |
NASDAQ |
Nov 21, 16:00
99.91
0.00 (0.00%)
After-Hours: 19:53
Price Chart
Key Stats
Price and Performance | |
---|---|
Market Cap | 19.90B |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | 17.25% |
Valuation | |
PE Ratio | 55.66 |
PE Ratio (Forward) | Upgrade |
PS Ratio | 5.254 |
Price to Book Value | 2.511 |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | -- |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | 0.3317 |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | 45.45% |
Profile
CooperCompanies is one of the largest eyecare companies in the us. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business with a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and Clariti, Cooper controls roughly one fourth of the us contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women’s care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the us, and controls 17% of the us IUD market. |
URL | https://www.coopercos.com |
Investor Relations URL | https://investor.coopercos.com/ |
HQ State/Province | California |
Sector | Health Care |
Industry | Health Care Equipment & Supplies |
Equity Style | Mid Cap/Blend |
Next Earnings Release | Dec. 05, 2024 |
Last Earnings Release | Aug. 28, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | Jul. 26, 2023 |
Ratings
Profile
CooperCompanies is one of the largest eyecare companies in the us. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business with a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and Clariti, Cooper controls roughly one fourth of the us contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women’s care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the us, and controls 17% of the us IUD market. |
URL | https://www.coopercos.com |
Investor Relations URL | https://investor.coopercos.com/ |
HQ State/Province | California |
Sector | Health Care |
Industry | Health Care Equipment & Supplies |
Equity Style | Mid Cap/Blend |
Next Earnings Release | Dec. 05, 2024 |
Last Earnings Release | Aug. 28, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | Jul. 26, 2023 |